Title |
Systematic Review of Cost-Effectiveness Analyses of Treatments for Psoriasis
|
---|---|
Published in |
PharmacoEconomics, December 2014
|
DOI | 10.1007/s40273-014-0244-9 |
Pubmed ID | |
Authors |
Wei Zhang, Nazrul Islam, Canice Ma, Aslam H. Anis |
Abstract |
Psoriasis is a chronic inflammatory disease of the skin that has a major effect on an individual's physical and mental function. The disease is associated with increased healthcare resource use and costs, therefore cost-effectiveness analysis (CEA) can be used to assist decision makers with determining which treatments are optimal within a constrained healthcare system budget. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 2 | 33% |
Colombia | 1 | 17% |
Spain | 1 | 17% |
Unknown | 2 | 33% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 5 | 83% |
Science communicators (journalists, bloggers, editors) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 67 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
United Kingdom | 1 | 1% |
Denmark | 1 | 1% |
Unknown | 65 | 97% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 14 | 21% |
Student > Ph. D. Student | 11 | 16% |
Researcher | 8 | 12% |
Student > Bachelor | 7 | 10% |
Other | 4 | 6% |
Other | 9 | 13% |
Unknown | 14 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 15 | 22% |
Business, Management and Accounting | 7 | 10% |
Pharmacology, Toxicology and Pharmaceutical Science | 5 | 7% |
Economics, Econometrics and Finance | 4 | 6% |
Biochemistry, Genetics and Molecular Biology | 3 | 4% |
Other | 12 | 18% |
Unknown | 21 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2019.
All research outputs
#1,967,994
of 22,772,779 outputs
Outputs from PharmacoEconomics
#137
of 1,816 outputs
Outputs of similar age
#29,209
of 359,774 outputs
Outputs of similar age from PharmacoEconomics
#5
of 30 outputs
Altmetric has tracked 22,772,779 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,816 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 359,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.